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Background: Few studies have evaluated the prevalence of HBV in the general Cameroonian population or among
antenatal attendants. The aim of this study was to determine the prevalence, correlates and patterns of Hepatitis B
surface antigen among pregnant women attending antenatal care in Yaounde-Cameroon.
Methods: This was a cross-sectional multicenter study carried out in a referral hospital and two secondary hospitals
in Yaounde, the capital of Cameroon. The study lasted 15 months (March 2011 to June 2012), and recruited 959
pregnant women. Patient recruitment was consecutive. The HBsAg was tested using the Monalisa HBsAg Ultra
ELISA kit. Other hepatitis B markers were equally tested.
We used the statistical package for social sciences (SPSS) version 14.0 software to conduct a quantitative analysis of
the derived data. Simple descriptive statistics such as means, standard deviations, and proportions were used to
describe the data. We tested for association in categorical variables using the chi-squared (χ2) test. The odds ratio
(OR) and the corresponding 95% confidence intervals (95% CI) were used to summarise the strength of association
between specific binary exposure and outcome variables. The level of statistical significance for the study was set at
p < 0.05.
Results: The prevalence of hepatitis B infection (HBsAg) among antenatal clinic attenders in our setting was 7.7%.
Amongst these women, just 5.4% were previously aware of their HBsAg status. The rate of HBV infectivity was high,
with 28% of HBsAg positive women having evidence of HBeAg in their plasma, and up to 45.8% of these women
lacking antibodies against hepatitis B e antigen (anti-HBe). About 41% of the pregnant women had had previous
contact with HBV as evidenced by the positive status for anti-HBc.
Just 2.7% of the pregnant women had previously been vaccinated against HBV. The mean age for HBsAg positivity
in our setting was 26.9 ±4.7 years, and the most affected age group was the 25 – 29 years age group. There was
no statistically significant association between age or other socio-demographic risk factors and HBsAg status.
Numerous risk factors for HBV acquisition exists in our settings, but amongst these, only a history of a contact with
hepatitis B infection was found to be significantly associated with HBsAg positivity (OR 1.63, 95% C.I 1.15-2.30).
Finally, the coinfection rate of HBV/HIV was 0.74%.
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Conclusion: The prevalence of hepatitis B among pregnant women in Cameroon is high, and the pattern tends
towards high infectivity and therefore increased risk of perinatal HBV transmission. These highlight the need to step
up preventive efforts against hepatitis B infection and perinatal HBV transmission in our community.
Keywords: Hepatitis B, Pregnancy, Prevalence, Risk factors, Low resource settingBackground
Infection with Hepatitis B Virus (HBV) remains a ser-
ious public health problem worldwide and is a major
cause of morbidity and mortality in Africa and Asia
[1-3]. Perinatal transmission is one of the commonest
modes of HBV transmission worldwide [4]. The Global
Advisory Group on the Expanded Program on Immun-
isation recommended that countries with a more than
2% prevalence of HBV carriers should add hepatitis B
vaccine into their routine infant immunization schedules,
a recommendation which was endorsed by the World
Health Assembly [5]. Consequently the routine screening
of pregnant women for hepatitis B surface antigen
(HBsAg) is recommended by the World Health Organisa-
tion [6].
Chronic Hepatitis B virus infection affects approxi-
mately 350 million people worldwide, half of whom
acquired the infection from perinatal transmission or in
early childhood [4,7]. This perinatal transmission of
HBV leads to severe long term sequelae [8]. Children
born to mothers who are positive for hepatitis B surface
antigen (HBsAg) and Hepatitis B e antigen (HBeAg)
have a 70-90% chance of perinatal acquisition of HBV
infection, and over 85-90% of them will eventually be-
come chronic carriers of the disease. Chronic carriers of
HBV have an increased lifetime risk of dying from hepa-
tocellular carcinoma and liver cirrhosis (25% risk) [9,10],
and remain the main reservoir for continued transmis-
sion of HBV [11]. Many of them eventually become
mothers themselves, thus perpetuating the cycle [12].
Cameroon is a high endemic area for HBV infection with
a prevalence rate > 8% This implies perinatal and early
childhood transmission are therefore the main means of
HBV infection in Cameroon [13,14], with the potential risk
of chronic HBV infection. Yet the response of Cameroon
to the call of universal screening of pregnant women for
HBV has been timid. The screening of antenatal clinic at-
tenders for HBV is not yet a routine practice in most
health settings in Cameroon. Moreover the implementa-
tion of routine vaccination of newborns against hepatitis
was only adopted in 2005.
Few studies have however evaluated the prevalence of
HBV in the general Cameroonian population or among
antenatal attendants [15-18]. Amongst these, Ndumbe et al
reported a prevalence of 9.6% in the general Cameroonian
population [16], while Chiaramonte et al reported analarming 19.9% prevalence among school children in an
urban setting in Cameroon [15]. Working on antenatal
clinic attendants, Ndumbe et al reported a prevalence rate
of HBV of 5.4% among rural pregnant women in
Cameroon [17], while Kfutwah et al recently reported a
prevalence of 7.85% among urban pregnant women [18].
The study by Kfutwah et al is the lone study carried out in
an urban setting in Cameroon. However, their results are
based on evaluation of blood samples collected from ante-
natal clinic attenders in the year 2000 during a pilot pro-
gram for the prevention of mother-to-child transmission of
the Human Immuno-deficiency virus (HIV). Consequently,
their results are highly informative of the state of the epi-
demiology as it was some 12 years ago, but probably do not
reflect the state of the epidemic in Cameroon today.
Given that HBV leads to serious sequelae, it is import-
ant that its epidemiology should continuously be exam-
ined [19]. It is therefore timely for current studies to be
performed to better characterise the epidemiology of
HBV among pregnant women in Cameroon and to as-
sess whether there has been a shift in the epidemiology
of this condition over time. This will help inform the
Cameroonian Ministry of health on the state of the art
of this epidemic, and whether or not there is a need to
prioritise this problem.
The aim of this study was to determine the prevalence,
correlates and patterns of Hepatitis B surface antigen
among pregnant women attending antenatal care in
Yaounde-Cameroon. We carried the research a step
further by assessing the infectivity of these women to
shed more light on the possible risks of perinatal HBV
transmission.
Methods
This was a cross-sectional study conducted at the
Yaounde University Teaching Hospital (CHUY), the
Biyem-Assi (BADH) and the Cite Verte District Hospi-
tals (CVDH) of Yaounde, the capital of Cameroon. The
University Teaching Hospital is a tertiary hospital in the
Yaounde, receiving a wide variety of patients not only
from other hospitals in Yaounde itself, but also from
other hospitals nationwide. The Cite Verte and Biyem-
Assi District Hospitals are secondary care facilities
within Yaounde, catering for a wide variety of patients as
well, both rural and urban. By selecting patients from
these three facilities we believe our sample was largely
Fomulu et al. BMC Pregnancy and Childbirth 2013, 13:158 Page 3 of 10
http://www.biomedcentral.com/1471-2393/13/158representative of all categories of pregnant women in
Yaounde.
Ethical approval to conduct this study was obtained
from the Ethical committee of the International Research
Centre on HIV/AIDS of the Chantal Biya Foundation.
Each patient provided written informed consent to partici-
pate in the study.
The study recruited 959 pregnant women attending
antenatal care in one of the above cited hospitals during
the study period. The sample size was calculated using
the standard formula for sample size calculation N =
z2pq/d2 (where z = the standard normal deviation at 1.96
(which corresponds to a 95% confidence interval), p =
the prevalence of Hepatitis B in the general Cameroon-
ian population, estimated at 10%; q = 1 – p; and d = the
degree of precision expected = 0.05).
The study lasted 15 months, from March 2011 to June
2012 and we employed a consecutive sampling for data
collection, requesting consent from all antenatal clinic
attenders in the selected health facilities during the study
period. We included women with a confirmed pregnancy
who provided written informed consent to participate in
the study. Pregnancy was confirmed by any of the fol-
lowing means: positive pregnancy test (serum or urine
B-HCG); ultrasound; quickening; and the presence of
fetal heart tones by either auscultation or Doppler.
We excluded all women who refused to give consent,
and those who presented very early with a doubtful preg-
nancy. We equally excluded women with gestational tro-
phoblastic disease/molar pregnancy, ectopic pregnancy
and complete/incomplete/missed abortions.
Following informed consent, all participants were
interviewed using an interviewer administered pretested
questionnaire. There were no personal identifiers on the
questionnaires. This questionnaire was applied to gather
relevant socio-demographic data of the women as well
as predisposing factors for hepatitis B infection obtained
following a literature review. These included a previous
history of spontaneous abortion or still birth, history of
blood transfusion, a history of previous surgery, history
of previous jaundice, a history of scarifications/tattoos,
having a contact with a known history of hepatitis B
infection or jaundice (used as a proxy indicator for hepa-
titis B infection) and a previous history of sexually trans-
mitted infection (used as a proxy indicator for multiple
sexual partners). We collected information on these risk
factors to subsequently test their association with HBV
infection among pregnant women in our community.
After completion of the questionnaire, 5 ml of blood
was aseptically collected from the brachial/antebrachial
vein using a disposable syringe into Ethylene Di-amine
Tetra-acetic Acid (EDTA) vials, in order to prevent clot-
ting. These vials were properly labeled with the patients’
name and date of collection. The blood was either sub-mitted directly to the laboratory, or temporarily stored
in a refrigerator overnight and later transferred the
following day in cooling packs to the ‘Chantal Biya’
International Reference Centre for Research on HIV/
AIDS Prevention and Management (CIRCB) Yaounde
for biological analysis.
At the laboratory, the blood was them brought out of
the cooling packs and allowed to equilibrate with room
temperature. Plasma was them separated for HBV assay
by centrifugation at 6.000 revolutions per minute for
5 minutes. After centrifugation, the plasma was tested
for HBsAg using the Monalisa HBsAg Ultra ELISA kit
(BIO-RAD Laboratories). Positive and negative plasma
controls were run alongside each test. Most samples
were equally evaluated for the Hepatitis B core antibody
(anti-HBc) in order to determine previous exposure to
HBV within the study population. After identification of
HBsAg positive samples, and given the limited availabil-
ity of testing kits, a random sample of plasma amongst
these was chosen for evaluation of infectivity by testing
for the Hepatitis B e antigen (HBeAg). For the same rea-
son as above, not all the HBsAg positive samples were
tested for anti-HBe.
Rapid tests for HIV types 1 and 2 were equally run on
the samples using the DETERMINE HIV ½ test kit. Seven
of the women who consented to the study choose to spe-
cifically opt out of the HIV testing, which is a routine test
recommended for all pregnant women in Cameroon. They
were not included in the specific analysis dealing with
HIV and HBV.
Results were made available to the patients before deliv-
ery. All women who tested positive for HBsAg were coun-
seled on their status, the modes of disease transmission,
the need for neonatal immunization and close-contact
screening against hepatitis. They were then referred for
further evaluation and management by a gastroenterolo-
gist in the Yaounde University Teaching Hospital. Provi-
sions were equally made for immunoprophylaxis and
vaccination against Hepatitis B for the newborns at birth.
We used the statistical package for social sciences
(SPSS) version 14.0 software to conduct a quantitative
analysis of the derived. The variables were summarised
and examined. Simple descriptive statistics such as
means, standard deviations and proportions were used
to describe the data as appropriate.
Where indicated by the research question, variables
were cross-tabulated and hypotheses tested by applying
appropriate statistical tests. We tested for association in
categorical variables using the chi-squared (χ2) test,
reporting corresponding p-values. In case of small num-
bers in a given group (<5), the Fischer’s exact test was
used instead, and the corresponding p-value reported.
Wherever possible, analyses were done using the ungrouped
variables to retain optimum information content/power.





Age (Years) (Mean = 27.6; SD = 5.2)
≤ 15 3 0.3
16 – 20 50 5.2
21 – 24 224 23.4
25 – 29 356 37.1
30 – 34 198 20.6
35 – 39 114 11.9







Primary education 101 10.5
Secondary education 537 56.0
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lected from the pregnant women who were HBsAg nega-
tive, and matched, for age, educational level, marital and
professional status with the cases, was used to compare
the strength of the association between reported risk fac-
tors and infection with Hepatitis B virus. We opted for
this nested case–control design within our cross section
as it is a validated approach and may actually be advanta-
geous over a full cross sectional design [20]. The odds ra-
tio and the corresponding 95% confidence intervals (95%
CI) were used to summarise the strength of association
between specific binary exposure and outcome variables.
The level of statistical significance for the study was set at
p < 0.05.
The primary outcome measure was the detection of
the presence of Hepatitis B surface antigen (HBsAg) in
the plasma of pregnant women, and their association
with known risk factors for maternal infection. Second-
ary outcome measures included the assessment of
markers of hepatitis B infectivity (hepatitis B ‘e’ antigen
(HBeAg), antibody against the Hepatitis B ‘e’ antigen)
among HBsAg positive participants, and coinfection with
the Human Immuno-deficiency Virus (HIV).University and beyond 317 33.1
Occupational status
No formal employment 505 52.7
Students 232 24.2
Civil servants 157 16.4




Figure 1 illustrates all the pregnant women attending an-
tennal care during the study period and the sample even-
tually recruited into the study.
Among the 959 patients who participated in this study,
the ages varied between 15 and 43 years with a mean age of
27.6 ±5.2 years. The mean gestational age of our patients
was 29.2 weeks; (minimum = 6 weeks; maximum =
42 weeks). Most of these women (97.3%) had never been
vaccinated against Hepatitis B. Table 1 summarises the

















Figure 1 Sketch outlining the selection of the sample population.The Hepatitis B surface antigen (HBsAg) was detected
in the plasma of 74 of these women, giving an overall
HBsAg prevalence of 7.7%. Just 4 of these women (5.4%)
were previously aware of their HBsAg status. Among the
74 women who tested positive for HBsAg, results for
HBeAg testing was available for 25. Amongst these 25
women, 7 (28%) tested positive for HBeAg, thus indicat-
ing that this proportion of patients was highly infectious,
and therefore likely to transmit the virus to their off-
spring. Results for testing for anti-HBe were available for
48 HBsAg (+) patients. Amongst these, 45.8% (n = 22)
lacked anti-HBe. This implies a higher proportion of
women were thus at risk of active viral replication, than
was estimated by our assessment of HBeAg alone. The
remainder (54.2%) had anti-HBe, indicating they were
seroconverting.
Previous exposure to HBV was evaluated by assessing
the prevalence of anti-HBc within the study sample. This
marker was evaluated in 644 patients. Of these, 263
Table 3 Association between HBsAg status and the
predisposing factors








Yes 47 22 25 0.97 0.66 – 1.43




Yes 6 2 4 0.69 0.22 – 2.17
No 118 57 61
History of surgery 124
Yes 16 3 13 0.36 0.13 – 1.02




Yes 23 9 14 0.79 0.46 – 1.37
No 101 50 51
History of jaundice 124
Yes 14 8 6 1.23 0.75 – 2.02




Yes 35 23 12 1.63 1.15 – 2.30
No 89 36 53
History of STI 124
Yes 19 9 10 0.99 0.59 – 1.66
No 105 50 55
STI Sexually Transmitted Infection, OR Odds ratio; 95% C.I = 95%
confidence interval.
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logic evidence of previous HBV exposure.
The mean age among pregnant women who were
HBsAg positive was 26.9 years. The prevalence of
HBsAg was highest among the 25 – 29 year age group
(Table 2). There was no statistically significant associ-
ation between the socio-demographic characteristics
evaluated (age, gravidity, marital status, and educational
level), and HBsAg status.
As stated in the methods, a control group matched for
age and professional status was used to compare the
strength of the association between reported risk factors
and infection with Hepatitis B virus. This gave a new
sample of 124 patients, with 59 cases and 65 controls. In
this new sample, 23 HBsAg positive patients (39.0%)
reported having a contact with a known history of hepa-
titis B infection or jaundice (used as a proxy indicator
for hepatitis B infection). The association between a his-
tory of a contact with hepatitis and HBsAg status was
statistically significant, with a significantly higher risk of
being HBsAg-positive amongst those with a contact with
HBV or jaundice, relative to those without such a con-
tact (OR 1.63, 95% C.I 1.15 – 2.30). The most commonly
cited contacts were immediate family members includ-
ing the mother, the father, brothers and sisters, cousins
and aunts. One patient reported that her mother in law
was known to be HBV positive. One patient who identi-
fied her father as being HBV positive reported he was a
worker in a blood bank.
A previous history of spontaneous abortion or still
birth, history of blood transfusion, a history of previous
surgery, history of previous jaundice, a history of scarifi-
cations/tattoos and a previous history of sexually trans-
mitted infection were not found to be statistically
significantly associated with the HBsAg status (Table 3).
In our study sample 80 (8.4%) women tested positive
for HIV (n = 952). Seven of these 80 women were
equally infected with the hepatitis B virus. This implies
the coinfection rate HIV/HBV in our study population is
0.74% (7/952).Table 2 HBsAg prevalence by age among the pregnant
women
Age group Number (n = 959) HBsAg + (%) HBsAg – (%)
≤ 15 3 0 (0.0%) 3 (100.0%)
16 – 20 50 5 (10.0%) 45 (90.0%)
21 – 24 224 13 (5.8%) 211 (94.2%)
25 – 29 356 38 (10.7%) 318 (89.3%)
30 – 34 198 14 (7.1%) 184 (92.9%)
35 – 39 114 3 (2.6%) 111 (97.4%)
40+ 14 1 (7.1%) 13 (92.9%)
(FE χ 2 = 10.4 df = 6 p = 0.11).The relationship between HIV status and HBsAg sta-
tus was not statistically significant (Table 4).Discussion
The results of our study indicate that the prevalence of
HBsAg among antenatal clinic attenders in Yaounde is
7.7%. Cameroon is generally considered an area of hyper-
endemicity for hepatitis B infection (prevalence >8%)
[14]. This fact is strongly supported by the prevalence of
HBsAg among blood donors such as the 10.8% reported
by Noah et al [21] 10.7% reported by Mbanya et al [22]Table 4 HIV status and HBsAg status
HIV (+) HIV (−) Total
HBsAg (+) (n = 74) 7 (8.8%) 67 (7.7%) 74
HBsAg(−) (n = 878) 73 (91.3%) 805 (92.3%) 878
Total 80 872 952
(OR 0.88, 95% C.I 0.42 – 1.84).
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all among blood donors in Yaounde Cameroon. Our
prevalence of HBsAg of 7.7% among pregnant women is
comparable to these figures, thus suggesting that sero-
prevalence of HBsAg among pregnant women may be
used as a proxy measure of this condition in the general
population.
After Kfutwah et al [18] this is the second study on
hepatitis B carried out among pregnant women in an
urban setting in Cameroon. Our HBsAg seroprevalence
is identical to the prevalence of 7.85% among pregnant
women reported by Kfutwah et al [18] earlier on this
year in Yaounde, despite working on blood samples col-
lected from pregnant women more than 10 years ago.
Our results are however higher than the earlier reports
of HBsAg prevalence among pregnant women in
Cameroon by Ndumbe et al who reported a 5.4% preva-
lence among pregnant women in a rural setting [17].
One obvious difference between our study and that of
Ndumbe et al is the different settings and study popula-
tions. One may estimate that urban dwellers probably
have a higher risk of acquiring the infection that those
in rural settings. This hypothesis however needs to be
evaluated.
Our prevalence of HBsAg among pregnant women of
7.7% is comparable to the 8.3% HBsAg prevalence
among pregnant women reported by Luka et al [24] in
an Urban setting in Nigeria, and by Eke et al [19] still
among pregnant women in a rural setting still in Nigeria.
They are comparable with the 6.4% HBsAg prevalence
reported in Ghana [25], the 6.5% HBsAg prevalence
reported in Congo [26], the 9.3% HBsAg prevalence
reported in Kenya [27] and the 10.7% HBsAg prevalence
in Burkina Faso [28], all among pregnant women. Our
findings are significantly lower than the 25% prevalence
of HBsAg reported by Madzime et al among pregnant
women in Zimbabwe [29]. On the contrary, our results
are higher than the 1.2% HBsAg prevalence reported
among antenatal clinic attenders in South Africa [30].
A high proportion of our patients showed evidence of
previous exposure to HBV as evidenced by the 40.8% of
anti-HBc prevalence within our study population. This
proportion is lower than the 85% anti-HBc seropreva-
lence reported by Ndumbe et al among pregnant women
in a rural setting in Cameroon. It is however higher than
the anti-HBc seroprevalence among pregnant women in
the developed world, with reports ranging from 7.1% in
Switzerland [31], through 13.4% in France [32], and
29.65% anti-HBc seroprevalence among pregnant women
in China [33].
Our study equally indicates that just 2.7% of pregnant
women have ever been vaccinated against HBV. This
shows a massive lack of awareness concerning HBV infec-
tion in the general Cameroonian population and the needfor anti HBV vaccination. It further indirectly highlights
the present inadequacy of community sensitization activities
by our health authorities on sensitizing the Cameroonian
population about HBV infection, and the importance of
anti HBV vaccination.
These two preceding facts combined highlight the fact
that HBV is very much present in our community. They
further indicate that even though Cameroon is a hyper-
endemic area for HBV, where transmission is generally
considered to be vertical, horizontal transmission is also
an important mode of HBV acquisition as presumed by
Kfutwah et al [18]. Given that very few women have ever
been vaccinated against HBV, the risk of HBV acquisi-
tion in our community is high. We however did not find
any reports that had looked into the vaccination status
against HBV of pregnant women within our community.
Our study therefore strongly highlights this important
fact which hitherto was apparently neglected by HBV re-
searchers in Cameroon.
The hepatitis e status, and the HBV viral load are both
factors known to be associated with vertical HBV trans-
mission [18]. We did not evaluate vertical transmission in
our study, but used the presence of HBeAg which is a
marker of high infectivity, as a proxy measure for the risk
of vertical transmission of HBV. HBeAg positive patients
are known to have a high viral load, and transmit HBV to
their offspring [18]. We found that 28% of HBsAg positive
patients in our sample were equally HBeAg positive. This
was largely in contrast with Kfutwah et al who found no
HBeAg positive samples amongst patients who tested
positive for HBsAg. It is known that the risk of vertical
transmission and resulting chronic carrier infection from
an HBsAg (+) mother to her baby is approximately 90% in
HBeAg positive pregnant women with high HBV DNA
titres [34,35]. Hence our results do not support the asser-
tion by Kfutwah et al who stated that ‘this form of trans-
mission (vertical transmission) could play a negligible role
in HBV transmission in Cameroon’ [18]. Our findings sug-
gest that vertical transmission possibly is a very important
means of HBV transmission in Cameroon.
Reports from sub-Saharan Africa indicates that sero-
conversion of anti-HBe occurs before the age of 15 to
16 years, with the consequence that most reproductive
age women do carry anti-HBe [36]. Our findings indi-
cated that up to 45.8% of HBsAg positive patients lacked
this antibody. This was an indirect indicator of the in-
fectivity of these women. In addition, HBV chronicity is
associated with early infection (fetal, perinatal, neonatal
or early infancy) [17]. The rate of HBV positivity among
pregnant patients in our settings is quite high, sug-
gesting that early infection plays an important role.
These facts further support our belief that vertical trans-
mission is indeed a very important means of HBV trans-
mission in Cameroon.
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26.9 years, and HBsAg was highest among the 25 –
29 years age group (Table 2). This HBsAg seroprevalence
was equally high (10%) among the 16 – 20 years age
group (Table 2). Our findings are in accordance with
Vazquez-Martinez et al who reported that the average
age of women infected with hepatitis B virus was 26 years
[37]. Our findings somewhat tally with Ndumbe et al in
Cameroon [17], and Eke et al in Nigeria [19] who found
the highest prevalence of HBsAg among the 10 – 19 age
group (10.4%), and the 15 – 19 age group (16.7%) re-
spectively. A possible reason for the slightly higher
HBsAg prevalence in the 25 – 29 years age group is the
fact that between these ages, many women in urban
areas of Cameroon are likely to get married and become
pregnant. They are therefore likely to present for the
first time in antenatal care, and can thus be easily picked
up by screening.
Other socio-demographic characteristics were evalu-
ated to determine whether these were associated with a
risk of HBV acquisition. This included the marital status
of the patients, their educational level, their professions,
and their gravidity. Despite reports from other studies
that some of these factors may be linked with the risk of
HBV acquisition, we did not find a statistically signifi-
cant association between any of these factors and the
risk of HBV infection among our study subjects.
Despite the high prevalence of HBsAg among pregnant
women in our settings, just one predisposing factor for
HBV infection showed statistical significance. This result
was in accordance with Summer et al who showed that
most of those testing positive for HBsAg had just one or
two predisposing factors for hepatitis B surface antigen
[38]. It was noted from this study that previous contact
with someone with hepatitis B infection was a statisti-
cally significant predisposing factor for HBsAg infection.
Our findings are in accordance with other reports which
indicate that the risk of HBV transmission is high in
people who are in contact chronically infected HBV sub-
jects [19,39-41].
There was no significant association between the other
risk factors and HBsAg positivity. This is in accordance
with studies carried out in neighboring Nigeria [19,42].
We could not make any direct comparisons with previ-
ous reports in Cameroon as none of these evaluated the
significance of supposed predisposing factors for HBV
among pregnant women. To the best of our knowledge
therefore, our study is the first study evaluating the rela-
tive importance risk factors for HBV acquisition among
pregnant women in Cameroon.
The association between HIV and HBV was not statis-
tically significant in our study. Ahmed et al in Malawi
equally failed to find any statistical evidence for the asso-
ciation between HIV positivity and HBV infection [43].The HIV/HBV coinfection rate in our study population
was 0.74%. Our results are comparable to the 0.7% HIV/
HBV coinfection rate among pregnant women in Awka,
Nigeria [44], but are lower than the 4.2% HIV/HBV co-
infection rate among pregnant women reported by Eke
et al [19] still in Nigeria. Reports from other African set-
tings equally indicate that HIV/HBV coinfection rate
among pregnant women is low. Pertinent amongst these,
are reports from Burkina Faso showing a co-infection
rate of 0.88% [45], and another in Benin City, Nigeria
which showed a low coinfection rate of 0.20% [46]. Our
findings are in contrast with those of Ndumbe et al in
Cameroon, who did not find any coinfection with HBV
among the 13 pregnant women found to be HIV positive
[17]. One possible reason was that the number of HIV
positive cases in the study by Ndumbe et al was rela-
tively small, and the HIV epidemic was probably still in
its early stages in Cameroon at the time.
In our survey, the HBsAg positivity rate was similar in
HIV-positive (8.8%) and HIV-negative pregnant women
(7.7%). This finding was similar to that reported by
Kfutwah et al who found an HBsAg positivity rate of 9%
and 7% among HIV-positive and HIV-negative pregnant
women respectively [18]. Similar findings have equally
been reported in Cote d’Ivoire [47]. The role of sexual
transmission of HBV can therefore not be neglected
among this population of pregnant women. The fact that
HIV and some hepatitis viruses share common modes of
transmission has often raised questions concerning the
potential of the hepatitis viruses to increase the virulence
of HIV infection, and/or influence the progression of
symptomatic HIV infection in asymptomatic patients
[48,49]. The low coinfection rate of HIV/HBV in our
study population is a rather consolatory finding given
that the prevalence of both of these infections is high
among pregnant women in Cameroon.
The implications of our research findings are numer-
ous. The 7.7% prevalence of HBsAg among pregnant
women in our community is an indication that pregnant
women serve as an important reservoir to fuel the HBV
infection in the general Cameroonian population. Fur-
thermore, the fact that over 28% of HBsAg positive preg-
nant women were also positive for HBeAg implies the
risk of perinatal and childhood transmission of HBV is
very high within our community. Efforts are therefore
needed to contain this situation. A way forward could be
to strengthen the policy on routine HBV testing in ante-
natal care. This had previously been suggested [18]. The
inclusion of HBsAg as a routine prenatal test should be
accompanied by appropriate facilities for management of
positive cases. This screening would also enable the
timely passive and active immunization of newborns
born to HBsAg positive mothers in order to minimize if
not avert seroconversion (57). Other preventive measures
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ling services for HBV on the same day, the availability of
rapid HBV-testing facilities within the clinic and increased
confidentiality at every level of the program. There should
equally be provision for active/passive immunisation for
the infants of infected mothers. Screening of pregnant
women will also enable the screening of close contacts of
those infected, and these individuals can then either be
vaccinated or managed as appropriate.
The similarity between our HBsAg seroprevalence and
pregnant women and that reported by Kfutwah et al [18]
implies there has not been any significant change in the
epidemiology of this condition within the past 10 years
in Cameroon. It therefore highlights the fact that pre-
ventive efforts against horizontal HBV transmission have
had little or no impact within our community for the
time being. This is further supported by the low vaccin-
ation rates against HBV despite the existence of a safe
and effective vaccine. In addition, contact with a chronic-
ally infected subject was the lone risk factor significantly
associated with HBV infection within our community.
These call for a need to step up preventive efforts against
horizontal HBV transmission within our community if we
hope to halt and subsequently reverse this epidemic. Pos-
sible measures could include universal vaccination against
HBV of at risk groups such as heal workers, blood bank
workers, and those with a contact known to be infected
with HBV.
Based on this study, we propose the following recom-
mendations: prenatal screening for HBV should be in-
cluded as part of the routine tests for pregnant women
in our community; prenatal counseling on HBV should
be instituted within our community as this could help to
raise the awareness of HBV among future mothers and
might be linked to higher follow up rates in HBV
immunization independent of the mothers’ HBV status;
anti hepatitis B vaccination for all new borns should be
reinforced, this irrespective of the mother’s HBV status;
provisions should be made for appropriate follow-up
and subsequent management of HBV positive pregnant
women identified through screening, during and after
their pregnancy; Hepatitis B immunoglobulin should be
made available to enable passive immunisation of infants
from HBV infected mothers; there should be increased
collaboration between maternity and vaccination ser-
vices to enable timely vaccination of infants of HBV
infected mothers.
Strenghts and weaknesses of our study
The major strength of our study lies in the methodology
and the large sample size. Patients were recruited prospect-
ively and as such, our results demonstrate the state of the
art of the epidemic as it presently is. In addition, it was a
multicenter study, capturing a diverse population of preg-nant women (both rural and urban) within and around
Yaounde which is the capital city of Cameroon, hence truly
reflects the epidemiology of HBV within our community.
A further strength lies in the fact that certain practical
challenges were identified. In the course of this research
it became obvious that hepatitis B immunoglobulin for
passive immunisation of the newborns of HBV infected
mothers is not commonly available in our settings. Even
the provision of HBV vaccine within 12 hours of delivery
was rather challenging. Our study also highlighted wor-
ries concerning breastfeeding in HBV infected mothers.
This permitted the education of patients and health
personnel alike as they were informed that there is no evi-
dence that breastfeeding from an HBV infected mother
poses an additional risk of HBV infection to her infant,
even in the absence of immunisation [50].
Our data was limited by the fact data on reported risk
factors depended on the memories of study participants,
and there was no other means to verify the truthfulness
of this information. Moreover, it was noticed that the
probing into these risk factors created an atmosphere of
suspicion of HBV infection among study participants,
and may have biased some of the responses. Also, the
rate of HBeAg was measured in one third of the HBsAg
positive women and anti-HBe was measured in two thirds
of HBsAg-positive women all due to financial constraints.
Despite the fact that these samples were random hence
probably representative samples, considering all the sam-
ples would have been the ideal.
Conclusion
The prevalence of hepatitis B among pregnant women
in Cameroon is high and the pattern tends towards high
infectivity and therefore increased perinatal transmis-
sion. The epidemiology of this condition has been stag-
nant over the past 10 years, and indicates that pregnant
women serve as a source of the infection in the general
population as well. These facts highlight the need for
preventive efforts against hepatitis B infection in preg-
nant women in Cameroon.
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